Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab

• Published in: Emerging infectious diseases Vol. 24; no. 8; pp. 1594 - 1596
• Main Authors: Martinot, Martin, Ahle, Guido, Petrosyan, Inesa, Martinez, Camille, Gorun, Dragos M, Mohseni-Zadeh, Mahsa, Fafi-Kremer, Samira, Tebacher-Alt, Martine
• Format: Journal Article
• Language: English
• Published: United States U.S. National Center for Infectious Diseases 01-08-2018; Centers for Disease Control and Prevention
• Subjects: Aged; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; Care and treatment; Female; Health aspects; Hodgkin Disease - diagnostic imaging; Hodgkin Disease - drug therapy; Hodgkin Disease - pathology; Hodgkin Disease - virology; Humans; Hydrocortisone - therapeutic use; immune checkpoint inhibitor; Immunotherapy; JC virus; JC Virus - isolation & purification; Leukoencephalopathy, Progressive Multifocal - diagnostic imaging; Leukoencephalopathy, Progressive Multifocal - etiology; Leukoencephalopathy, Progressive Multifocal - pathology; Leukoencephalopathy, Progressive Multifocal - virology; Lymphomas; Magnetic Resonance Imaging; Male; meningtitis/encephalaitis; Middle Aged; Monoclonal antibodies; nivolumab; Nivolumab - administration & dosage; Nivolumab - adverse effects; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - immunology; Progressive multifocal leukoencephalopathy; Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab; Research Letter; T cells; Viremia - diagnostic imaging; Viremia - etiology; Viremia - pathology; Viremia - virology; viruses; France; immune checkpoint inhibitor; viruses; nivolumab; HIV/AIDS and other retroviruses; JC virus; progressive multifocal leukoencephalopathy; meningtitis/encephalitis
• ISSN: 1080-6040; 1080-6059
• DOI: 10.3201/eid2408.180460

Progressive multifocal leukoencephalopathy (PML) is increasingly being reported in patients undergoing immunotherapy. We report a case of progressive multifocal leukoencephalopathy after treatment with nivolumab, a PD-1 blocker that is used to restore impaired T-cell responses in patients with cancer and infections. Data for 4 other cases were obtained from pharmacovigilance databases.